VKTX
NASDAQ HealthcareViking Therapeutics, Inc. - Common Stock
Biotechnology
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRร), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRร for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
๐ Market Data
| Price | $35.62 |
|---|---|
| Volume | 14,748,231 |
| Market Cap | 4.14B |
| Beta | 0.680 |
| RSI (14-Day) | 52.9 |
| 200-Day MA | $33.31 |
| 50-Day MA | $33.86 |
| 52-Week High | $43.15 |
| 52-Week Low | $24.88 |
| Forward P/E | -8.06 |
| Price / Book | 10.13 |
๐ฏ Investment Strategy Scores
VKTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (77/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (18/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find VKTX in your text
Paste any article, transcript, or post โ the tool will extract VKTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.